Drugs for the treatment of hyperlipidemia

William L. Stone, Thomas K. Chin

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Hyperlipidemia is a major risk factor for the development of cardiovascular disease. Considerable evidence suggests that drugs with the ability to lower low density lipoprotein-cholesterol also lower cardiovascular deaths. Tliis review will focus on new developments in the design of pharmacological agents and therapies that can favorably affect hyperlipidemia. A broad range of therapeutic agents will be discussed, including food additives, nutraceuticals, conventional pharmaceuticals as well as gene therapy. The potential adverse effects caused by these agents will also be discussed. Appetite suppressants, intestinal lipase inhibitors, inhibitors of dietary cholesterol absorption, inhibitors of chylomicron assembly, HMG CoA reductase inhibitors (statins) and adenovirus-mediated gene therapy are specifically discussed in detail. Treatments and issues specific to the elderly and to children are also described. Hie specific application of pharmacogenics to the problem of hyperlipidemia is presented as a likely direction for fiiture research empliasis.

Original languageEnglish (US)
Pages (from-to)788-794
Number of pages7
Issue number7
StatePublished - 2001

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Drugs for the treatment of hyperlipidemia'. Together they form a unique fingerprint.

Cite this